Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases
BackgroundToll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors i...
Saved in:
| Published in: | Journal for immunotherapy of cancer Vol. 12; no. 7; p. e008837 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
BMJ Publishing Group Ltd
22.07.2024
BMJ Publishing Group LTD BMJ Publishing Group |
| Subjects: | |
| ISSN: | 2051-1426, 2051-1426 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | BackgroundToll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors is limited in part by the distinctive biology of intrahepatic myeloid-derived suppressor cells (MDSC) and challenges with tumor-specific therapeutic delivery. We have shown that the regional delivery of type C TLR9 agonist via pressure-enabled drug delivery (PEDD) system improves delivery to the tumor, enhances depletion of MDSCs and overall, stimulates the immune system in combination with or without CPI. Currently, CPIs are delivered intravenously, although there is a growing interest in its subcutaneous (SQ) administration. We compared nelitolimod formerly known as SD-101 administered using PEDD in combination with systemic (Sys) or SQ CPI in murine liver metastases (LM).MethodsThe LM model was developed by injecting MC38-Luc cells via the spleen of 8–12 week old male C57/BL6 mice followed by splenectomy. After a week, fluorescently labeled nelitolimod (10 µg/mouse) was delivered via PEDD and co-administered anti-programmed cell death-1 (α-PD-1) either via Sys or SQ. Tumor burden was monitored by in vivo imaging system. Serum cytokine levels were analyzed by Luminex. Tissues were harvested on Day 3 (D3) or Day 10 (D10) post-PEDD to enrich CD45+ cells and were analyzed via NanoString targeted transcriptomics (D3) or flow cytometry (FC, D10) to interrogate immune cell populations (D10). For NanoString analysis, the innate immune panels were selected, and for FC, MDSCs (CD11b+Gr1+), B cells (B220+), dendritic cells (DC, CD11c+), T (CD3+) cells, and M1-like macrophages (F4/80+CD38+Egr2−) were quantified.ResultsNelitolimod delivered via PEDD resulted in changes in innate and adaptive immune cells within LM, including depletion of liver MDSC and increased M1-like macrophages in the liver, which are supportive of antitumor immunity. While CPI monotherapy failed to control tumor progression, nelitolimod and CPI combination improved LM control, survival and antitumor immunity beyond the nelitolimod monotherapy effect, irrespective of CPI delivery route.ConclusionThe SQ route of CPI delivery was equivalent to Sys in combination with nelitolimod, suggesting SQ-CPI may be a rational choice in combination with PEDD of nelitolimod for liver tumor treatment. |
|---|---|
| AbstractList | Toll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors is limited in part by the distinctive biology of intrahepatic myeloid-derived suppressor cells (MDSC) and challenges with tumor-specific therapeutic delivery. We have shown that the regional delivery of type C TLR9 agonist via pressure-enabled drug delivery (PEDD) system improves delivery to the tumor, enhances depletion of MDSCs and overall, stimulates the immune system in combination with or without CPI. Currently, CPIs are delivered intravenously, although there is a growing interest in its subcutaneous (SQ) administration. We compared nelitolimod formerly known as SD-101 administered using PEDD in combination with systemic (Sys) or SQ CPI in murine liver metastases (LM).BACKGROUNDToll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors is limited in part by the distinctive biology of intrahepatic myeloid-derived suppressor cells (MDSC) and challenges with tumor-specific therapeutic delivery. We have shown that the regional delivery of type C TLR9 agonist via pressure-enabled drug delivery (PEDD) system improves delivery to the tumor, enhances depletion of MDSCs and overall, stimulates the immune system in combination with or without CPI. Currently, CPIs are delivered intravenously, although there is a growing interest in its subcutaneous (SQ) administration. We compared nelitolimod formerly known as SD-101 administered using PEDD in combination with systemic (Sys) or SQ CPI in murine liver metastases (LM).The LM model was developed by injecting MC38-Luc cells via the spleen of 8-12 week old male C57/BL6 mice followed by splenectomy. After a week, fluorescently labeled nelitolimod (10 µg/mouse) was delivered via PEDD and co-administered anti-programmed cell death-1 (α-PD-1) either via Sys or SQ. Tumor burden was monitored by in vivo imaging system. Serum cytokine levels were analyzed by Luminex. Tissues were harvested on Day 3 (D3) or Day 10 (D10) post-PEDD to enrich CD45+ cells and were analyzed via NanoString targeted transcriptomics (D3) or flow cytometry (FC, D10) to interrogate immune cell populations (D10). For NanoString analysis, the innate immune panels were selected, and for FC, MDSCs (CD11b+Gr1+), B cells (B220+), dendritic cells (DC, CD11c+), T (CD3+) cells, and M1-like macrophages (F4/80+CD38+Egr2-) were quantified.METHODSThe LM model was developed by injecting MC38-Luc cells via the spleen of 8-12 week old male C57/BL6 mice followed by splenectomy. After a week, fluorescently labeled nelitolimod (10 µg/mouse) was delivered via PEDD and co-administered anti-programmed cell death-1 (α-PD-1) either via Sys or SQ. Tumor burden was monitored by in vivo imaging system. Serum cytokine levels were analyzed by Luminex. Tissues were harvested on Day 3 (D3) or Day 10 (D10) post-PEDD to enrich CD45+ cells and were analyzed via NanoString targeted transcriptomics (D3) or flow cytometry (FC, D10) to interrogate immune cell populations (D10). For NanoString analysis, the innate immune panels were selected, and for FC, MDSCs (CD11b+Gr1+), B cells (B220+), dendritic cells (DC, CD11c+), T (CD3+) cells, and M1-like macrophages (F4/80+CD38+Egr2-) were quantified.Nelitolimod delivered via PEDD resulted in changes in innate and adaptive immune cells within LM, including depletion of liver MDSC and increased M1-like macrophages in the liver, which are supportive of antitumor immunity. While CPI monotherapy failed to control tumor progression, nelitolimod and CPI combination improved LM control, survival and antitumor immunity beyond the nelitolimod monotherapy effect, irrespective of CPI delivery route.RESULTSNelitolimod delivered via PEDD resulted in changes in innate and adaptive immune cells within LM, including depletion of liver MDSC and increased M1-like macrophages in the liver, which are supportive of antitumor immunity. While CPI monotherapy failed to control tumor progression, nelitolimod and CPI combination improved LM control, survival and antitumor immunity beyond the nelitolimod monotherapy effect, irrespective of CPI delivery route.The SQ route of CPI delivery was equivalent to Sys in combination with nelitolimod, suggesting SQ-CPI may be a rational choice in combination with PEDD of nelitolimod for liver tumor treatment.CONCLUSIONThe SQ route of CPI delivery was equivalent to Sys in combination with nelitolimod, suggesting SQ-CPI may be a rational choice in combination with PEDD of nelitolimod for liver tumor treatment. Toll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors is limited in part by the distinctive biology of intrahepatic myeloid-derived suppressor cells (MDSC) and challenges with tumor-specific therapeutic delivery. We have shown that the regional delivery of type C TLR9 agonist via pressure-enabled drug delivery (PEDD) system improves delivery to the tumor, enhances depletion of MDSCs and overall, stimulates the immune system in combination with or without CPI. Currently, CPIs are delivered intravenously, although there is a growing interest in its subcutaneous (SQ) administration. We compared nelitolimod formerly known as SD-101 administered using PEDD in combination with systemic (Sys) or SQ CPI in murine liver metastases (LM). The LM model was developed by injecting MC38-Luc cells via the spleen of 8-12 week old male C57/BL6 mice followed by splenectomy. After a week, fluorescently labeled nelitolimod (10 µg/mouse) was delivered via PEDD and co-administered anti-programmed cell death-1 (α-PD-1) either via Sys or SQ. Tumor burden was monitored by in vivo imaging system. Serum cytokine levels were analyzed by Luminex. Tissues were harvested on Day 3 (D3) or Day 10 (D10) post-PEDD to enrich CD45 cells and were analyzed via NanoString targeted transcriptomics (D3) or flow cytometry (FC, D10) to interrogate immune cell populations (D10). For NanoString analysis, the innate immune panels were selected, and for FC, MDSCs (CD11b Gr1 ), B cells (B220 ), dendritic cells (DC, CD11c ), T (CD3 ) cells, and M1-like macrophages (F4/80 CD38 Egr2 ) were quantified. Nelitolimod delivered via PEDD resulted in changes in innate and adaptive immune cells within LM, including depletion of liver MDSC and increased M1-like macrophages in the liver, which are supportive of antitumor immunity. While CPI monotherapy failed to control tumor progression, nelitolimod and CPI combination improved LM control, survival and antitumor immunity beyond the nelitolimod monotherapy effect, irrespective of CPI delivery route. The SQ route of CPI delivery was equivalent to Sys in combination with nelitolimod, suggesting SQ-CPI may be a rational choice in combination with PEDD of nelitolimod for liver tumor treatment. Background Toll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors is limited in part by the distinctive biology of intrahepatic myeloid-derived suppressor cells (MDSC) and challenges with tumor-specific therapeutic delivery. We have shown that the regional delivery of type C TLR9 agonist via pressure-enabled drug delivery (PEDD) system improves delivery to the tumor, enhances depletion of MDSCs and overall, stimulates the immune system in combination with or without CPI. Currently, CPIs are delivered intravenously, although there is a growing interest in its subcutaneous (SQ) administration. We compared nelitolimod formerly known as SD-101 administered using PEDD in combination with systemic (Sys) or SQ CPI in murine liver metastases (LM).Methods The LM model was developed by injecting MC38-Luc cells via the spleen of 8–12 week old male C57/BL6 mice followed by splenectomy. After a week, fluorescently labeled nelitolimod (10 µg/mouse) was delivered via PEDD and co-administered anti-programmed cell death-1 (α-PD-1) either via Sys or SQ. Tumor burden was monitored by in vivo imaging system. Serum cytokine levels were analyzed by Luminex. Tissues were harvested on Day 3 (D3) or Day 10 (D10) post-PEDD to enrich CD45+ cells and were analyzed via NanoString targeted transcriptomics (D3) or flow cytometry (FC, D10) to interrogate immune cell populations (D10). For NanoString analysis, the innate immune panels were selected, and for FC, MDSCs (CD11b+Gr1+), B cells (B220+), dendritic cells (DC, CD11c+), T (CD3+) cells, and M1-like macrophages (F4/80+CD38+Egr2−) were quantified.Results Nelitolimod delivered via PEDD resulted in changes in innate and adaptive immune cells within LM, including depletion of liver MDSC and increased M1-like macrophages in the liver, which are supportive of antitumor immunity. While CPI monotherapy failed to control tumor progression, nelitolimod and CPI combination improved LM control, survival and antitumor immunity beyond the nelitolimod monotherapy effect, irrespective of CPI delivery route.Conclusion The SQ route of CPI delivery was equivalent to Sys in combination with nelitolimod, suggesting SQ-CPI may be a rational choice in combination with PEDD of nelitolimod for liver tumor treatment. BackgroundToll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors is limited in part by the distinctive biology of intrahepatic myeloid-derived suppressor cells (MDSC) and challenges with tumor-specific therapeutic delivery. We have shown that the regional delivery of type C TLR9 agonist via pressure-enabled drug delivery (PEDD) system improves delivery to the tumor, enhances depletion of MDSCs and overall, stimulates the immune system in combination with or without CPI. Currently, CPIs are delivered intravenously, although there is a growing interest in its subcutaneous (SQ) administration. We compared nelitolimod formerly known as SD-101 administered using PEDD in combination with systemic (Sys) or SQ CPI in murine liver metastases (LM).MethodsThe LM model was developed by injecting MC38-Luc cells via the spleen of 8–12 week old male C57/BL6 mice followed by splenectomy. After a week, fluorescently labeled nelitolimod (10 µg/mouse) was delivered via PEDD and co-administered anti-programmed cell death-1 (α-PD-1) either via Sys or SQ. Tumor burden was monitored by in vivo imaging system. Serum cytokine levels were analyzed by Luminex. Tissues were harvested on Day 3 (D3) or Day 10 (D10) post-PEDD to enrich CD45+ cells and were analyzed via NanoString targeted transcriptomics (D3) or flow cytometry (FC, D10) to interrogate immune cell populations (D10). For NanoString analysis, the innate immune panels were selected, and for FC, MDSCs (CD11b+Gr1+), B cells (B220+), dendritic cells (DC, CD11c+), T (CD3+) cells, and M1-like macrophages (F4/80+CD38+Egr2−) were quantified.ResultsNelitolimod delivered via PEDD resulted in changes in innate and adaptive immune cells within LM, including depletion of liver MDSC and increased M1-like macrophages in the liver, which are supportive of antitumor immunity. While CPI monotherapy failed to control tumor progression, nelitolimod and CPI combination improved LM control, survival and antitumor immunity beyond the nelitolimod monotherapy effect, irrespective of CPI delivery route.ConclusionThe SQ route of CPI delivery was equivalent to Sys in combination with nelitolimod, suggesting SQ-CPI may be a rational choice in combination with PEDD of nelitolimod for liver tumor treatment. |
| Author | Layman, Ilan B Cox, Bryan F Liu, Yujia Perati, Shriya Murtha, Timothy D Morrissey, Molly Davar, Diwakar Ballarin, Alizee Katz, Steven C Fraser, Kayla Yakirevich, Evgeny Guha, Prajna Treaba, Diana O Ghosh, Chandra C Cournoyer, Lauren LaPorte, Jason |
| Author_xml | – sequence: 1 givenname: Chandra C orcidid: 0009-0003-7471-0443 surname: Ghosh fullname: Ghosh, Chandra C organization: Trisalus Life Sciences, Westminster, Colorado, USA – sequence: 2 givenname: Lauren surname: Cournoyer fullname: Cournoyer, Lauren organization: Department of Surgery, Brown University School of Medicine, Providence, RI, USA – sequence: 3 givenname: Yujia surname: Liu fullname: Liu, Yujia organization: Trisalus Life Sciences, Westminster, Colorado, USA – sequence: 4 givenname: Alizee surname: Ballarin fullname: Ballarin, Alizee organization: Trisalus Life Sciences, Westminster, Colorado, USA – sequence: 5 givenname: Ilan B surname: Layman fullname: Layman, Ilan B organization: Department of Surgery, Brown University School of Medicine, Providence, RI, USA – sequence: 6 givenname: Jason surname: LaPorte fullname: LaPorte, Jason organization: Trisalus Life Sciences, Westminster, Colorado, USA – sequence: 7 givenname: Molly surname: Morrissey fullname: Morrissey, Molly organization: Trisalus Life Sciences, Westminster, Colorado, USA – sequence: 8 givenname: Kayla surname: Fraser fullname: Fraser, Kayla organization: Trisalus Life Sciences, Westminster, Colorado, USA – sequence: 9 givenname: Shriya surname: Perati fullname: Perati, Shriya organization: Trisalus Life Sciences, Westminster, Colorado, USA – sequence: 10 givenname: Bryan F surname: Cox fullname: Cox, Bryan F organization: Trisalus Life Sciences, Westminster, Colorado, USA – sequence: 11 givenname: Evgeny surname: Yakirevich fullname: Yakirevich, Evgeny organization: Department of Pathology, Brown University School of Medicine, Providence, Rhode Island, USA – sequence: 12 givenname: Diana O surname: Treaba fullname: Treaba, Diana O organization: Department of Pathology, Brown University School of Medicine, Providence, Rhode Island, USA – sequence: 13 givenname: Timothy D surname: Murtha fullname: Murtha, Timothy D organization: Department of Surgery, Brown University School of Medicine, Providence, RI, USA – sequence: 14 givenname: Prajna orcidid: 0000-0001-6831-9374 surname: Guha fullname: Guha, Prajna organization: Trisalus Life Sciences, Westminster, Colorado, USA – sequence: 15 givenname: Steven C surname: Katz fullname: Katz, Steven C organization: Department of Surgery, Brown University School of Medicine, Providence, RI, USA – sequence: 16 givenname: Diwakar orcidid: 0000-0002-7846-8055 surname: Davar fullname: Davar, Diwakar email: davard@upmc.edu organization: Department of Hematology and Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39038918$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UsluFDEUbKEgEkLunJAlLhxo8NLT4z6hKGKJFIkDcLa8vM54cNsd2z3R_DWfgHsmuwSSJS-vqlx-rpfVgQ8equo1wR8IYe3Htc26ppg2Ncacs-Wz6ojiBalJQ9uDB-vD6iSlNcaYYMY45y-qQ9ZhxjvCj6o_Pyalpyw9hCkhvQL9ewzWZ2T9yiqbbfDIJgRXk91IB6WQA0rblGGwGhlwdgNxi65X4JEOg7IeDLq2eYV8qeXg7BDMLa6UNlaiMUJKU4QavFSuHJo4Xd5r9SGWzehgd3noi5Uc5QpGmcuVwxZcsKY2EAvcoDSNO71C0uBcQtKb4qRQgpvJO1E0QJapDEivque9dAlObubj6teXzz_PvtUX37-en51e1GpBea4NxpQr2ZN22RoFpGNgSLME2WLKCHRcS6WpMRx4syBMQwea9ooyoC1ReMmOq_O9rglyLcZoBxm3IkgrdgchXgoZy4McCNk00PcKug5MQzBIULLpuh6IJC1dmKL1aa81TmoAo2FuiHsk-rji7Upcho0ghLYcN01ReHejEMPVBCmLwaa5X_uPFwxz1i7JsuTiuHr7BLoOU_SlVzsUpQvMaUG9eWjpzsttsgoA7wE6hpQi9HcQgsWcXzHnV8z5Ffv8Fkr7hKJtlnMKyqOs-x_x_Z6ohvW923_C_wK7vw0r |
| CitedBy_id | crossref_primary_10_1016_j_apsb_2025_09_007 crossref_primary_10_1021_acs_bioconjchem_5c00001 crossref_primary_10_3390_cancers17071250 crossref_primary_10_3389_fimmu_2025_1633315 |
| Cites_doi | 10.1093/annonc/mdw685 10.1158/2159-8290.CD-21-0425 10.1158/2159-8290.CD-18-0280 10.1158/1538-7445.AM2023-1858 10.1200/JCO.20.00605 10.2147/DDDT.S267433 10.1172/JCI80011 10.1097/CAD.0000000000000648 10.1172/jci.insight.93433 10.1126/scitranslmed.aad7118 10.1038/s41417-022-00484-z 10.1007/s10120-018-00922-8 10.4049/jimmunol.170.8.4061 10.3389/fimmu.2021.643771 10.1038/s41388-018-0449-z 10.1038/s41573-021-00345-8 10.1016/j.surg.2023.05.011 10.3389/fimmu.2020.00783 10.1172/JCI87324 10.1084/jem.192.7.1027 10.1038/70932 10.1016/j.cellimm.2021.104295 10.1038/s41392-021-00670-9 10.3390/vaccines9080807 10.1136/jitc-2020-001097 10.1007/s10637-022-01287-7 10.1001/jamaoncol.2019.2187 10.1002/cpt.3148 10.1073/pnas.1608555113 10.1007/s12325-017-0610-z 10.1158/2326-6066.CIR-16-0325 10.1371/journal.pone.0157957 10.1038/328267a0 10.1002/cam4.573 10.1200/JCO.20.00550 10.1007/s00262-013-1508-5 10.1007/s40261-023-01254-x 10.1016/j.celrep.2022.111295 10.1001/jamaoncol.2019.0836 10.1038/s41571-019-0218-0 10.1002/onco.13817 10.1007/s40265-023-01884-7 10.4049/jimmunol.1701019 10.1038/s41591-020-1131-x 10.1056/NEJMoa2216334 10.1189/jlb.3A0114-012RR 10.1200/jco.20.00550 10.1136/jitc-2022-SITC2022.1165 10.1136/jitc-2023-SITC2023.1534 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2024 |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2024 |
| DBID | 9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1136/jitc-2024-008837 |
| DatabaseName | BMJ Open Access Journals (Free internet resource, activated by CARLI) BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| ExternalDocumentID | oai_doaj_org_article_a44effbe99ed410eaeba499fe1a1625d PMC11268044 39038918 10_1136_jitc_2024_008837 jitc |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Trisalus Life Sciences grantid: Not applicable – fundername: ; grantid: Not applicable |
| GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV ADRAZ AFKRA AHBYD AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR KQ8 M1P M48 M~E OK1 PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RMJ RPM RSV SOJ UKHRP AAYXX ADUKV AFFHD AHSBF CITATION EJD H13 ITC PHGZM PJZUB PPXIY ROL CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-b528t-d0028baf1676dbe193ed147ea60231e98cabc2dd8e84513ce9ec2fb23e261b073 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 4 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001311626300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2051-1426 |
| IngestDate | Fri Oct 03 12:53:15 EDT 2025 Tue Nov 04 02:05:29 EST 2025 Fri Sep 05 12:41:09 EDT 2025 Sat Nov 29 14:40:55 EST 2025 Mon Jul 21 05:33:26 EDT 2025 Sat Nov 29 07:24:42 EST 2025 Tue Nov 18 20:47:31 EST 2025 Thu Mar 13 14:30:34 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Myeloid-derived suppressor cell - MDSC Toll-like receptor - TLR Immune Checkpoint Inhibitor Tumor microenvironment - TME |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b528t-d0028baf1676dbe193ed147ea60231e98cabc2dd8e84513ce9ec2fb23e261b073 |
| Notes | Original research ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 CCG, YL, AB, JL, MM, KF, BFC, PG, SCK are employee of Trisalus Life Sciences. LC, IBL, SP, EY, DOT, TM have no conflict of interest. Conflict of interests of DD are: Grants/Research Support (institutional): Arcus, CellSight Technologies, Immunocore, Merck, Regeneron Pharmaceuticals, Tesaro/GSK. Consultant: ACM Bio, Ascendis Pharma, Clinical Care Options (CCO), Gerson Lehrman Group (GLG), Merck, Medical Learning Group (MLG), Xilio Therapeutics. CE Speakers’ Bureau: Castle Biosciences. Intellectual Property: US Patent 63/124,231, “Compositions and Methods for Treating Cancer”, December 11, 2020 US Patent 63/208,719, “Compositions and Methods For Responsiveness to Immune Checkpoint Inhibitors (ICI), Increasing Effectiveness of ICI and Treating Cancer”, June 9, 2021. SCK and DD are joint senior authors. Supplement: Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/jitc-2024-008837). Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. |
| ORCID | 0000-0001-6831-9374 0000-0002-7846-8055 0009-0003-7471-0443 |
| OpenAccessLink | https://doaj.org/article/a44effbe99ed410eaeba499fe1a1625d |
| PMID | 39038918 |
| PQID | 3083225082 |
| PQPubID | 2040222 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a44effbe99ed410eaeba499fe1a1625d pubmedcentral_primary_oai_pubmedcentral_nih_gov_11268044 proquest_miscellaneous_3083671790 proquest_journals_3083225082 pubmed_primary_39038918 crossref_primary_10_1136_jitc_2024_008837 crossref_citationtrail_10_1136_jitc_2024_008837 bmj_journals_10_1136_jitc_2024_008837 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-22 |
| PublicationDateYYYYMMDD | 2024-07-22 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-22 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationTitleAbbrev | J Immunother Cancer |
| PublicationTitleAlternate | J Immunother Cancer |
| PublicationYear | 2024 |
| Publisher | BMJ Publishing Group Ltd BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BMJ Publishing Group Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Ostrand-Rosenberg, Fenselau (R14) 2018; 200 Ghosh, Heatherton, Connell (R24) 2022; 29 Chai, Hardaway, Heatherton (R49) 2021; 9 Daud, Loo, Pauli (R12) 2016; 126 Topalian, Hodi, Brahmer (R10) 2019; 5 Chen, Han (R41) 2015; 125 Zou, Wolchok, Chen (R4) 2016; 8 Ai, Chen, Yan (R5) 2020; 14 Ma, Zhang, Greten (R45) 2021; 361 Shimizu, Nakajima, Yamamoto (R32) 2022; 40 Rummel, Kim, Aversa (R37) 2017; 28 Blackwell, Krieg (R39) 2003; 170 Ribas, Medina, Kummar (R19) 2018; 8 Guha, Gardell, Darpolor (R43) 2019; 38 Freeman, Long, Iwai (R3) 2000; 192 Davies, Berge, Boehnke (R34) 2017; 34 Ribas, Medina, Kirkwood (R18) 2021; 11 Katz, Moody, Guha (R20) 2020; 8 Tumeh, Hellmann, Hamid (R11) 2017; 5 Hou, Hou, Huang (R15) 2020; 11 Shin, Kumar, Guo (R28) 2023; 43 Johnson, Braiteh, Grilley-Olson (R30) 2019; 5 De Cock, Kritikou, Sandoval (R35) 2016; 11 Yu, Green, Li (R17) 2021; 27 Pelster, Gruschkus, Bassett (R26) 2021; 39 Li, Shi, Zhang (R48) 2021; 6 Kang (R6) 2023; 83 Piulats, Espinosa, de la Cruz Merino (R27) 2021; 39 Wang, Campos, Gallotta (R38) 2016; 113 Loo, Tsai, Mahuron (R13) 2017; 2 Korman, Garrett-Thomson, Lonberg (R8) 2022; 21 Jaroch, Ghosh, Guha (R21) 2023; 83 Papadopoulos, Harb, Peer (R31) 2021; 26 De Cock, Pivot, Hauser (R36) 2016; 5 Thorn, Point, Burga (R46) 2014; 96 Meyer, Cagnon, Costa-Nunes (R16) 2014; 63 Capacio, Shankara Narayanan, Vicente (R22) 2023; 174 Franken, Kanters, Coenen (R29) 2018; 29 Xu, Wei, Feng (R47) 2022; 40 Dong, Zhu, Tamada (R2) 1999; 5 Mirza, Chase, Slomovitz (R7) 2023; 388 Zhao, Sanghavi, Roy (R33) 2024; 115 Martins, Sofiya, Sykiotis (R50) 2019; 16 Mehta, Kadel, Townsend (R23) 2021; 12 Brunet, Denizot, Luciani (R1) 1987; 328 Sasaki, Nakamura, Mishima (R9) 2019; 22 Katz (2025100304432731000_12.7.e008837.20) 2020; 8 Sasaki (2025100304432731000_12.7.e008837.9) 2019; 22 2025100304432731000_12.7.e008837.27 2025100304432731000_12.7.e008837.26 Topalian (2025100304432731000_12.7.e008837.10) 2019; 5 Mirza (2025100304432731000_12.7.e008837.7) 2023; 388 De Cock (2025100304432731000_12.7.e008837.35) 2016; 11 Zhao (2025100304432731000_12.7.e008837.33) 2024; 115 Ghosh (2025100304432731000_12.7.e008837.24) 2022; 29 Xu (2025100304432731000_12.7.e008837.47) 2022; 40 Mehta (2025100304432731000_12.7.e008837.23) 2021; 12 Capacio (2025100304432731000_12.7.e008837.22) 2023; 174 Johnson (2025100304432731000_12.7.e008837.30) 2019; 5 Guha (2025100304432731000_12.7.e008837.43) 2019; 38 2025100304432731000_12.7.e008837.38 2025100304432731000_12.7.e008837.39 2025100304432731000_12.7.e008837.37 Ma (2025100304432731000_12.7.e008837.45) 2021; 361 Franken (2025100304432731000_12.7.e008837.29) 2018; 29 Korman (2025100304432731000_12.7.e008837.8) 2022; 21 Jaroch (2025100304432731000_12.7.e008837.21) 2023; 83 Chai (2025100304432731000_12.7.e008837.49) 2021; 9 2025100304432731000_12.7.e008837.41 2025100304432731000_12.7.e008837.42 2025100304432731000_12.7.e008837.40 Li (2025100304432731000_12.7.e008837.48) 2021; 6 Papadopoulos (2025100304432731000_12.7.e008837.31) 2021; 26 Kang (2025100304432731000_12.7.e008837.6) 2023; 83 2025100304432731000_12.7.e008837.46 2025100304432731000_12.7.e008837.44 2025100304432731000_12.7.e008837.2 Brunet (2025100304432731000_12.7.e008837.1) 1987; 328 Shin (2025100304432731000_12.7.e008837.28) 2023; 43 2025100304432731000_12.7.e008837.50 2025100304432731000_12.7.e008837.3 cr-split#-2025100304432731000_12.7.e008837.25.2 cr-split#-2025100304432731000_12.7.e008837.25.1 Hou (2025100304432731000_12.7.e008837.15) 2020; 11 Zou (2025100304432731000_12.7.e008837.4) 2016; 8 Ai (2025100304432731000_12.7.e008837.5) 2020; 14 De Cock (2025100304432731000_12.7.e008837.36) 2016; 5 Shimizu (2025100304432731000_12.7.e008837.32) 2022; 40 Davies (2025100304432731000_12.7.e008837.34) 2017; 34 2025100304432731000_12.7.e008837.18 2025100304432731000_12.7.e008837.19 2025100304432731000_12.7.e008837.16 2025100304432731000_12.7.e008837.17 2025100304432731000_12.7.e008837.14 2025100304432731000_12.7.e008837.12 2025100304432731000_12.7.e008837.11 Loo (2025100304432731000_12.7.e008837.13) 2017; 2 |
| References_xml | – volume: 28 start-page: 836 year: 2017 ident: R37 article-title: Preference for subcutaneous or intravenous administration of rituximab among patients with untreated Cd20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (Prefmab) publication-title: Ann Oncol doi: 10.1093/annonc/mdw685 – volume: 11 start-page: 2998 year: 2021 ident: R18 article-title: Overcoming PD-1 blockade resistance with Cpg-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-21-0425 – volume: 8 start-page: 1250 year: 2018 ident: R19 article-title: SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase IB, multicenter study publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-18-0280 – volume: 83 start-page: 1858 year: 2023 ident: R21 article-title: Abstract 1858: enhanced delivery of anti PD-1 antibody to liver tumors in oncopig using pressure enabled drug delivery (PEDD) versus a systemic delivery publication-title: Cancer Res doi: 10.1158/1538-7445.AM2023-1858 – volume: 39 start-page: 599 year: 2021 ident: R26 article-title: Nivolumab and Ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study publication-title: J Clin Oncol doi: 10.1200/JCO.20.00605 – volume: 14 start-page: 3625 year: 2020 ident: R5 article-title: Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S267433 – volume: 125 start-page: 3384 year: 2015 ident: R41 article-title: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future publication-title: J Clin Invest doi: 10.1172/JCI80011 – volume: 29 start-page: 791 year: 2018 ident: R29 article-title: Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000648 – volume: 2 year: 2017 ident: R13 article-title: Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy publication-title: JCI Insight doi: 10.1172/jci.insight.93433 – volume: 8 year: 2016 ident: R4 article-title: PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aad7118 – volume: 29 start-page: 1854 year: 2022 ident: R24 article-title: Regional infusion of a class C Tlr9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition publication-title: Cancer Gene Ther doi: 10.1038/s41417-022-00484-z – volume: 22 start-page: 793 year: 2019 ident: R9 article-title: Predictive factors for hyperprogressive disease during Nivolumab as anti-Pd1 treatment in patients with advanced gastric cancer publication-title: Gastric Cancer doi: 10.1007/s10120-018-00922-8 – volume: 170 start-page: 4061 year: 2003 ident: R39 article-title: Cpg-A-induced monocyte IFN-gamma-inducible Protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha publication-title: J Immunol doi: 10.4049/jimmunol.170.8.4061 – volume: 12 year: 2021 ident: R23 article-title: Macrophage biology and mechanisms of immune suppression in breast cancer publication-title: Front Immunol doi: 10.3389/fimmu.2021.643771 – volume: 38 start-page: 533 year: 2019 ident: R43 article-title: Stat3 inhibition induces bax-dependent apoptosis in liver tumor myeloid-derived Suppressor cells publication-title: Oncogene doi: 10.1038/s41388-018-0449-z – volume: 21 start-page: 509 year: 2022 ident: R8 article-title: The foundations of immune checkpoint blockade and the Ipilimumab approval decennial publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-021-00345-8 – volume: 174 start-page: 666 year: 2023 ident: R22 article-title: Pressure-enabled drug delivery (PEDD) of a class C Tlr9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model publication-title: Surgery doi: 10.1016/j.surg.2023.05.011 – volume: 11 year: 2020 ident: R15 article-title: Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors publication-title: Front Immunol doi: 10.3389/fimmu.2020.00783 – volume: 126 start-page: 3447 year: 2016 ident: R12 article-title: Tumor immune profiling predicts response to anti-PD-1 therapy in human Melanoma publication-title: J Clin Invest doi: 10.1172/JCI87324 – volume: 192 start-page: 1027 year: 2000 ident: R3 article-title: Engagement of the PD-1 Immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J Exp Med doi: 10.1084/jem.192.7.1027 – volume: 5 start-page: 1365 year: 1999 ident: R2 article-title: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and Interleukin-10 secretion publication-title: Nat Med doi: 10.1038/70932 – volume: 361 start-page: 104295 year: 2021 ident: R45 article-title: Mdscs in liver cancer: a critical tumor-promoting player and a potential therapeutic target publication-title: Cell Immunol doi: 10.1016/j.cellimm.2021.104295 – volume: 6 start-page: 362 year: 2021 ident: R48 article-title: Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer publication-title: Sig Transduct Target Ther doi: 10.1038/s41392-021-00670-9 – volume: 9 year: 2021 ident: R49 article-title: Regional delivery of anti-PD-1 agent for colorectal liver metastases improves therapeutic index and anti-tumor activity publication-title: Vaccines (Basel) doi: 10.3390/vaccines9080807 – volume: 8 year: 2020 ident: R20 article-title: HITM-SURE: hepatic immunotherapy for metastases phase IB anti-CEA CAR-T study utilizing pressure enabled drug delivery publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-001097 – volume: 40 start-page: 1021 year: 2022 ident: R32 article-title: Phase I study of envafolimab (Kn035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors publication-title: Invest New Drugs doi: 10.1007/s10637-022-01287-7 – volume: 5 start-page: 1411 year: 2019 ident: R10 article-title: Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with Nivolumab publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.2187 – volume: 115 start-page: 488 year: 2024 ident: R33 article-title: Model-based dose selection of subcutaneous nivolumab in patients with advanced solid tumors publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.3148 – volume: 113 start-page: E7240 year: 2016 ident: R38 article-title: Intratumoral injection of a Cpg oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional Cd8+ T cells publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1608555113 – volume: 34 start-page: 2210 year: 2017 ident: R34 article-title: Subcutaneous Rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development publication-title: Adv Ther doi: 10.1007/s12325-017-0610-z – volume: 5 start-page: 417 year: 2017 ident: R11 article-title: Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-16-0325 – volume: 11 year: 2016 ident: R35 article-title: Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries publication-title: PLoS One doi: 10.1371/journal.pone.0157957 – volume: 328 start-page: 267 year: 1987 ident: R1 article-title: A new member of the immunoglobulin superfamily--CTLA-4 publication-title: Nature New Biol doi: 10.1038/328267a0 – volume: 5 start-page: 389 year: 2016 ident: R36 article-title: A time and motion study of subcutaneous versus intravenous trastuzumab in patients with Her2-positive early breast cancer publication-title: Cancer Med doi: 10.1002/cam4.573 – volume: 39 start-page: 586 year: 2021 ident: R27 article-title: Nivolumab plus Ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402) publication-title: J Clin Oncol doi: 10.1200/JCO.20.00550 – volume: 63 start-page: 247 year: 2014 ident: R16 article-title: Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with Ipilimumab publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-013-1508-5 – volume: 43 start-page: 289 year: 2023 ident: R28 article-title: Spending, utilization, and price trends for immune checkpoint inhibitors in US medicaid programs: an empirical analysis from 2011 to 2021 publication-title: Clin Drug Investig doi: 10.1007/s40261-023-01254-x – volume: 40 start-page: 111295 year: 2022 ident: R47 article-title: Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers publication-title: Cell Rep doi: 10.1016/j.celrep.2022.111295 – volume: 5 start-page: 999 year: 2019 ident: R30 article-title: Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-06801591 in patients with advanced solid tumors: a phase 1 dose-escalation trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.0836 – volume: 16 start-page: 563 year: 2019 ident: R50 article-title: Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-019-0218-0 – volume: 26 start-page: e1514 year: 2021 ident: R31 article-title: First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors publication-title: Oncologist doi: 10.1002/onco.13817 – volume: 83 start-page: 731 year: 2023 ident: R6 article-title: Retifanlimab: first approval publication-title: Drugs (Abingdon Engl) doi: 10.1007/s40265-023-01884-7 – volume: 200 start-page: 422 year: 2018 ident: R14 article-title: Myeloid-derived Suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment publication-title: J Immunol doi: 10.4049/jimmunol.1701019 – volume: 27 start-page: 152 year: 2021 ident: R17 article-title: Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination publication-title: Nat Med doi: 10.1038/s41591-020-1131-x – volume: 388 start-page: 2145 year: 2023 ident: R7 article-title: Dostarlimab for primary advanced or recurrent endometrial cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2216334 – volume: 96 start-page: 883 year: 2014 ident: R46 article-title: Liver metastases induce reversible hepatic B cell dysfunction mediated by Gr-1+Cd11B+ myeloid cells publication-title: J Leukoc Biol doi: 10.1189/jlb.3A0114-012RR – ident: 2025100304432731000_12.7.e008837.2 doi: 10.1038/70932 – ident: 2025100304432731000_12.7.e008837.17 doi: 10.1038/s41591-020-1131-x – volume: 14 start-page: 3625 year: 2020 ident: 2025100304432731000_12.7.e008837.5 article-title: Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S267433 – volume: 115 start-page: 488 year: 2024 ident: 2025100304432731000_12.7.e008837.33 article-title: Model-based dose selection of subcutaneous nivolumab in patients with advanced solid tumors publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.3148 – volume: 38 start-page: 533 year: 2019 ident: 2025100304432731000_12.7.e008837.43 article-title: Stat3 inhibition induces bax-dependent apoptosis in liver tumor myeloid-derived Suppressor cells publication-title: Oncogene doi: 10.1038/s41388-018-0449-z – ident: 2025100304432731000_12.7.e008837.16 doi: 10.1007/s00262-013-1508-5 – ident: 2025100304432731000_12.7.e008837.3 doi: 10.1084/jem.192.7.1027 – ident: 2025100304432731000_12.7.e008837.14 doi: 10.4049/jimmunol.1701019 – ident: 2025100304432731000_12.7.e008837.46 doi: 10.1189/jlb.3A0114-012RR – volume: 8 year: 2016 ident: 2025100304432731000_12.7.e008837.4 article-title: PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aad7118 – volume: 40 start-page: 1021 year: 2022 ident: 2025100304432731000_12.7.e008837.32 article-title: Phase I study of envafolimab (Kn035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors publication-title: Invest New Drugs doi: 10.1007/s10637-022-01287-7 – ident: 2025100304432731000_12.7.e008837.37 doi: 10.1093/annonc/mdw685 – volume: 26 start-page: e1514 year: 2021 ident: 2025100304432731000_12.7.e008837.31 article-title: First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors publication-title: Oncologist doi: 10.1002/onco.13817 – volume: 5 start-page: 389 year: 2016 ident: 2025100304432731000_12.7.e008837.36 article-title: A time and motion study of subcutaneous versus intravenous trastuzumab in patients with Her2-positive early breast cancer publication-title: Cancer Med doi: 10.1002/cam4.573 – volume: 328 start-page: 267 year: 1987 ident: 2025100304432731000_12.7.e008837.1 article-title: A new member of the immunoglobulin superfamily--CTLA-4 publication-title: Nature New Biol doi: 10.1038/328267a0 – ident: 2025100304432731000_12.7.e008837.12 doi: 10.1172/JCI87324 – volume: 34 start-page: 2210 year: 2017 ident: 2025100304432731000_12.7.e008837.34 article-title: Subcutaneous Rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development publication-title: Adv Ther doi: 10.1007/s12325-017-0610-z – volume: 174 start-page: 666 year: 2023 ident: 2025100304432731000_12.7.e008837.22 article-title: Pressure-enabled drug delivery (PEDD) of a class C Tlr9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model publication-title: Surgery doi: 10.1016/j.surg.2023.05.011 – ident: 2025100304432731000_12.7.e008837.39 doi: 10.4049/jimmunol.170.8.4061 – volume: 11 year: 2016 ident: 2025100304432731000_12.7.e008837.35 article-title: Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries publication-title: PLoS One doi: 10.1371/journal.pone.0157957 – volume: 83 start-page: 731 year: 2023 ident: 2025100304432731000_12.7.e008837.6 article-title: Retifanlimab: first approval publication-title: Drugs (Abingdon Engl) – volume: 5 start-page: 999 year: 2019 ident: 2025100304432731000_12.7.e008837.30 article-title: Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-06801591 in patients with advanced solid tumors: a phase 1 dose-escalation trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.0836 – ident: 2025100304432731000_12.7.e008837.26 doi: 10.1200/JCO.20.00605 – volume: 5 start-page: 1411 year: 2019 ident: 2025100304432731000_12.7.e008837.10 article-title: Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with Nivolumab publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.2187 – volume: 8 year: 2020 ident: 2025100304432731000_12.7.e008837.20 article-title: HITM-SURE: hepatic immunotherapy for metastases phase IB anti-CEA CAR-T study utilizing pressure enabled drug delivery publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-001097 – ident: 2025100304432731000_12.7.e008837.27 doi: 10.1200/jco.20.00550 – volume: 6 start-page: 362 year: 2021 ident: 2025100304432731000_12.7.e008837.48 article-title: Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer publication-title: Sig Transduct Target Ther doi: 10.1038/s41392-021-00670-9 – volume: 2 year: 2017 ident: 2025100304432731000_12.7.e008837.13 article-title: Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy publication-title: JCI Insight doi: 10.1172/jci.insight.93433 – ident: 2025100304432731000_12.7.e008837.44 – volume: 40 start-page: 111295 year: 2022 ident: 2025100304432731000_12.7.e008837.47 article-title: Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers publication-title: Cell Rep doi: 10.1016/j.celrep.2022.111295 – ident: 2025100304432731000_12.7.e008837.40 – ident: 2025100304432731000_12.7.e008837.50 doi: 10.1038/s41571-019-0218-0 – volume: 9 year: 2021 ident: 2025100304432731000_12.7.e008837.49 article-title: Regional delivery of anti-PD-1 agent for colorectal liver metastases improves therapeutic index and anti-tumor activity publication-title: Vaccines (Basel) doi: 10.3390/vaccines9080807 – volume: 12 year: 2021 ident: 2025100304432731000_12.7.e008837.23 article-title: Macrophage biology and mechanisms of immune suppression in breast cancer publication-title: Front Immunol doi: 10.3389/fimmu.2021.643771 – ident: 2025100304432731000_12.7.e008837.11 doi: 10.1158/2326-6066.CIR-16-0325 – volume: 11 year: 2020 ident: 2025100304432731000_12.7.e008837.15 article-title: Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors publication-title: Front Immunol doi: 10.3389/fimmu.2020.00783 – volume: 29 start-page: 791 year: 2018 ident: 2025100304432731000_12.7.e008837.29 article-title: Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000648 – ident: 2025100304432731000_12.7.e008837.19 doi: 10.1158/2159-8290.CD-18-0280 – volume: 83 start-page: 1858 year: 2023 ident: 2025100304432731000_12.7.e008837.21 article-title: Abstract 1858: enhanced delivery of anti PD-1 antibody to liver tumors in oncopig using pressure enabled drug delivery (PEDD) versus a systemic delivery publication-title: Cancer Res doi: 10.1158/1538-7445.AM2023-1858 – volume: 43 start-page: 289 year: 2023 ident: 2025100304432731000_12.7.e008837.28 article-title: Spending, utilization, and price trends for immune checkpoint inhibitors in US medicaid programs: an empirical analysis from 2011 to 2021 publication-title: Clin Drug Investig doi: 10.1007/s40261-023-01254-x – ident: 2025100304432731000_12.7.e008837.38 doi: 10.1073/pnas.1608555113 – volume: 21 start-page: 509 year: 2022 ident: 2025100304432731000_12.7.e008837.8 article-title: The foundations of immune checkpoint blockade and the Ipilimumab approval decennial publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-021-00345-8 – ident: 2025100304432731000_12.7.e008837.42 doi: 10.1136/jitc-2022-SITC2022.1165 – ident: 2025100304432731000_12.7.e008837.18 doi: 10.1158/2159-8290.CD-21-0425 – ident: #cr-split#-2025100304432731000_12.7.e008837.25.1 doi: 10.1136/jitc-2023-SITC2023.1534 – ident: 2025100304432731000_12.7.e008837.41 doi: 10.1172/JCI80011 – volume: 361 start-page: 104295 year: 2021 ident: 2025100304432731000_12.7.e008837.45 article-title: Mdscs in liver cancer: a critical tumor-promoting player and a potential therapeutic target publication-title: Cell Immunol doi: 10.1016/j.cellimm.2021.104295 – volume: 29 start-page: 1854 year: 2022 ident: 2025100304432731000_12.7.e008837.24 article-title: Regional infusion of a class C Tlr9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition publication-title: Cancer Gene Ther doi: 10.1038/s41417-022-00484-z – ident: #cr-split#-2025100304432731000_12.7.e008837.25.2 doi: 10.1136/jitc-2023-SITC2023.1534 – volume: 388 start-page: 2145 year: 2023 ident: 2025100304432731000_12.7.e008837.7 article-title: Dostarlimab for primary advanced or recurrent endometrial cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2216334 – volume: 22 start-page: 793 year: 2019 ident: 2025100304432731000_12.7.e008837.9 article-title: Predictive factors for hyperprogressive disease during Nivolumab as anti-Pd1 treatment in patients with advanced gastric cancer publication-title: Gastric Cancer doi: 10.1007/s10120-018-00922-8 |
| SSID | ssj0001033888 |
| Score | 2.319672 |
| Snippet | BackgroundToll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop... Toll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive... Background Toll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop... |
| SourceID | doaj pubmedcentral proquest pubmed crossref bmj |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e008837 |
| SubjectTerms | Animals Antigen presentation Bioluminescence Cell Line, Tumor Clinical/Translational Cancer Immunotherapy Costs Drug Delivery Systems Drug dosages Humans Immune Checkpoint Inhibitor Immune checkpoint inhibitors Immune Checkpoint Inhibitors - administration & dosage Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Inflammation Liver Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - secondary Melanoma Metastasis Mice Mice, Inbred C57BL Myeloid-derived suppressor cell - MDSC Myeloid-Derived Suppressor Cells - drug effects Myeloid-Derived Suppressor Cells - immunology Myeloid-Derived Suppressor Cells - metabolism Original Research Patient satisfaction Toll-like receptor - TLR Tumor microenvironment - TME Tumors |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYBSEuvB-BBRkJDhysNo8mzgkBYsUBVhxA6i3yY7L10ibdJinaf81PYMZJW4pQLxxbe6bj5pvxjD2ZYexVlqYKFQmELi21MEtASIwKhNWxsbhhZwC-a8nn7OxMTqf51-HArRnSKjc20RtqWxs6Ix_FY4893LHeLi8FdY2i29WhhcYRu05tswnn2TTbnbGMMQCTcnM7GaejC9caBEaUCNz7JDU_P9KLi709yZfu_5e_-Xfa5B_70Omd_13BXXZ78ED5ux4y99g1qO6zm1-GO_YH7BfaEtOhzwh113B8pubHsnZVy101c9pneHHXcLjsHKIUheRtzfuC0M5wC3PK9LjiP2dQcRQMI2-wnI57eYVjbT1HdNjNPBxaO8V9Nm63AgH-VS4cXnXnO17oWOOHJdUJxx-vSxQF_5oZUDa44YsrmNfOCovKtEbaplt6fkhE1xINV5XlQ0o-EXumfAGtQs-4geYh-3768duHT2LoCyH0JJKtsBQoalWGaZZaDeiCgg2TDFRKxewgl0ZpE1krQSaTMDaQg4lKHcWA4aJGm_aIHVd1BU8YjyxoFU-QV5knE2RhYlmqKNWTcWjRmwrYa8RHMeh1U_iQKU4LwlFBOCp6HAVstEFQYYbi6tTjY36A4s2WYtkXFjkw9z2BcjuPSoL7L-rVeTFYmEIlCZSlhjwHm4RjULgyDGdLCFWIQa4N2MkGlrv17DAZsJfbYbQw9Hx6oPk5aUaV3AL2uNeArSRxTgUaQxkwuacbe6Luj1Ru5quY07trcpwkTw_L9Yzd6vU1E1F0wo7bVQfP2Q2zbl2zeuH1_TdJa2jA priority: 102 providerName: ProQuest |
| Title | Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases |
| URI | https://jitc.bmj.com/content/12/7/e008837.full https://www.ncbi.nlm.nih.gov/pubmed/39038918 https://www.proquest.com/docview/3083225082 https://www.proquest.com/docview/3083671790 https://pubmed.ncbi.nlm.nih.gov/PMC11268044 https://doaj.org/article/a44effbe99ed410eaeba499fe1a1625d |
| Volume | 12 |
| WOSCitedRecordID | wos001311626300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central_OA刊 customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: RBZ dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: 7X7 dateStart: 20130501 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: BENPR dateStart: 20130501 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: PIMPY dateStart: 20130501 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbYBaG9IN4ElspIcOAQNa_GzpFFuwKJrSoEUjlFfkyolzbpNknR_mt-AmMn7bYILRculVI_YsffjGfiyTeEvGZpKlCQwJeFtinMEvA5egW-lrHSuGEzAJe15BMbj_l0mk12Un3ZmLCOHrh7cEORJFAUErIMdBIGIEAKtNILCEWItru22jdg2Y4z5d6uBOh6cb45l4zT4YVpFEIiSnzc9bhNe34gFxd7u5Ej7f-bpflnwOTODnR2n9zrTUf6rhvyA3ILyofk7nl_OP6I_EIloFo09gC9eYqLoX4sK1M21JQzI11oFjU1hcvWILzwHrSpaMfkbBTVMLchGlf05wxKijhElxk0te9paYllTTXHZdWbeli0NoK6MNp2BT64b7CweNV-v-4LLWK8WFqCb7x5VeBQcGYzsGHcii6uYF4Z7WuUgjW2rdul6w8b2fOEmopS0z6W3jZ2ndIFNAJN2hrqx-Tr2emX9x_8PqGDL0cRb3xtPTwpijBlqZaAtiPoMGEgUstCBxlXQqpIaw48GYWxggxUVMgoBvTzJCqjJ-SwrEp4RmikEQfxCPsqsmSEXaiYFyJK5SgINZpBHnmDy5v3AlnnzteJ09zCILcwyDsYeGS4AUCuelZ0m5xjfkOLt9sWy44R5Ia6JxZT23qWy9v9gQjPe4Tn_0K4R443iLyeTxw4VYwGnEdebYtRNdj16YDm6qTMUrB55GkH4O1I4swyK4bcI3wP2ntD3S8pzczRj9uPzniQJM__x-RekKNOKJkfRcfksFm18JLcUevG1KsBOWBT5n75gNw-OR1PPg-coOPV5OP55NtveM1h9Q |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lc9MwENa0hQEuPAsECogZeuDgSfyILR8YhlennaYZDmWmN2NJ68YlsdPYTid_it_GT2BXthPCMLn1wNGWtJalb1e70mqXsTeB78fISGDJRFMKMw8sgVaBpaWrNC7YAYDJWjIIhkNxdhZ-3WI_27sw5FbZykQjqHWuaI-86_YM9nDFej-9tChrFJ2utik0algcw-IKTbbi3dFnnN99xzn4cvrp0GqyCliy74jS0mRmyDix_cDXElCBAW17AcQ-hUKDUKhYKkdrAcLr266CEJSTSMcFNDYkcgTS3WY3UI4HZOwFZ8FqT6eHBp8Q7Wmo63cv0lIhEB3PwrVWULL1bTm5WFsDTaqAf-m3f7tp_rHuHdz730bsPrvbaNj8Q80SD9gWZA_ZrZPGh-AR-4WyUlWoE0NeFRwxq35M8zQreZqNUmk82HhacLisUuRCHBRe5rwOeJ0qrmFMniwLfjWCjONASCSqOW1n8wzLynyM6NdtPSyapzE33sbVDCwwV9WweFadr2ih4YAPU4qDjh_PE-wKTsUIyNtd8ckCxnmqLY3CYo5ti2pq6GEjOnYpeJxp3lw5oMaGKJ9AGaPmX0Cxy75dy3g_ZjtZnsFTxh0NMnb7SCsJvT6SUK5IYseX_Z6tUVvssH3EY9TIrSIyJqHrR4TbiHAb1bjtsG6L2Eg1weMph8l4Q4u3yxbTOnDKhrofiQmW9SjkuXmRz86jRoJGsedBkkgIQ9Ce3YMY_wzN9QTs2EYjXnfYXssGq_9Z8UCHvV4WowSl-amBZur4AUWq67AnNccte-KGFIDSFh0m1nhxravrJVk6MlHa6W6e6Hnes839esVuH56eDKLB0fD4ObtTy4rAcpw9tlPOKnjBbqp5mRazl0bWcPb9uln1N96sxuU |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1fb9MwELe2Dk288H9QGGAk9sBD1MZJE-cBIWBUVNuqPoA0nkJsX9aMNumapFO_Gp-Kj8DZSVqKUN_2wGNi--LY9zvf2ec7Ql77nhchkMASsdIpzFywOFoFlhKOVLhg-wAma8mpPxzy8_NgtEN-NndhtFtlIxONoFaZ1HvkHadreA9XrE5cu0WMjvvvZleWziClT1qbdBoVi5zA8hrNt_zt4Bjn-oix_qcvHz9bdYYBS_QYLyylTQ4Rxbbne0oAKjOgbNeHyNNh0SDgMhKSKcWBuz3bkRCAZLFgDqDhIRAdSHeX7KFK7rIW2RsNzkbf1js8XTT_OG_ORh2vc5kUEtmSuRauvFynXt8V08uNFdEkDviXtvu30-Yfq2D_7v88fvfInVr3pu8rsNwnO5A-IPtntXfBQ_ILpagsUVuGrMwpcrP8McuStKBJOk6E8W2jSU7hqkwQnzhAtMhoFQo7kVTBRPu4LOn1GFKKgyKQqKJ6o5umWFZkE8SFauph0SKJqPFDLudggbnEhsXz8mJNC00KfJjpCOn48SzGruC0jEH7wUs6XcIkS5SlUIwssG1ezgw9bKQPZHIapYrWlxF0Y0OUTqGI0CbIIX9Evt7IeB-QVpql8IRQpkBETg9pxYHbQxLS4XHEPNHr2gr1yDY5Qt4Ma4mWh8ZYdLxQ83CoeTiseLhNOg33hrIOK6-zm0y2tHizajGrQqpsqftBA2JVTwdDNy-y-UVYy9Ywcl2IYwFBAMq1uxDhn6EhH4Md2WjeqzY5bCCx_p81Htrk1aoYZauen4rRTB3P1zHs2uRxhb5VT5xAh6a0eZvwDVxudHWzJE3GJn67vrXHu677dHu_XpJ9RGh4OhiePCO3K7HhW4wdklYxL-E5uSUXRZLPX9SCh5LvN43V35_x0TQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Subcutaneous+checkpoint+inhibition+is+equivalent+to+systemic+delivery+when+combined+with+nelitolimod+delivered+via+pressure-enabled+drug+delivery+for+depletion+of+intrahepatic+myeloid-derived+suppressor+cells+and+control+of+liver+metastases&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Diwakar+Davar&rft.au=Yujia+Liu&rft.au=Jason+Laporte&rft.au=Prajna+Guha&rft.date=2024-07-22&rft.pub=BMJ+Publishing+Group&rft.eissn=2051-1426&rft.volume=12&rft.issue=7&rft_id=info:doi/10.1136%2Fjitc-2024-008837&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_a44effbe99ed410eaeba499fe1a1625d |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-1426&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-1426&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-1426&client=summon |